BRISBANE, Australia, Sept. 8, 2008 (GLOBE NEWSWIRE) -- Progen Pharmaceuticals Limited (ASX:PGL) (Nasdaq:PGLA) today announced that it received a letter dated 4 September 2008, from the Nasdaq Stock Market notifying the company that for the last 30 consecutive business days prior to 4 September, the bid price for the Company’s ordinary shares has closed below the minimum $US1.00 per share requirement for continued inclusion under Nasdaq Marketplace Rule 4320(e)(2)(E)(ii) (the “Rule”).
